Gerard Hernandez Mir

Gerard Hernandez Mir

Auto-generated profile, based on publicly available information

Gerard Hernandez Mir

Blizard Institute, Barts and The London School of Medicine, Queen Mary University of London, London, E1 2AT, UK

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2015 in Immunity
Verified
Journal Article
Closed access
AGAbhishek V. Garg
Abhishek V. Garg
NANilesh Amatya
Nilesh Amatya
KCKong Chen
Kong Chen
JCJ. Agustin Cruz
J. Agustin Cruz
PGPrerna Grover
Prerna Grover
SGSarah Gaffen
Sarah Gaffen

1 August 2016 in Cell Reports
Verified
Journal Article
Open access
FDFang Du
Fang Du
AGAbhishek V. Garg
Abhishek V. Garg
KKKaris Kosar
Karis Kosar
SMSaikat Majumder
Saikat Majumder
DKDavid G. Kugler
David G. Kugler
MMMandy J. McGeachy
Mandy J. McGeachy
Interleukin-23 (IL-23) is required for inflammatory Th17 cell function in experimental autoimmune encephalomyelitis (EAE), and IL-23 blockade reduces the number of effector Th17 cells in the CNS. We report that pro-inflammatory Th17 cells express high integrin β3 that is IL-23 dependent. Integrin β3 was not upregulated on all activated T cells; rather, integrin β3 was upregulated along with its functional partner integrin αv on effector Th17 cells and "ex-Th17" cells, and αvβ3(hi) RORγt(+) cells expanded during EAE. Integrin αvβ3 inhibitors ameliorated clinical signs of EAE, and integrin β3 deficiency on CD4(+) T cells alone was sufficient to block EAE induction. Furthermore, integrin-β3-deficient Th17 cells, but not Th1 cells, were impaired in their ability to induce EAE. Integrin β3(-/-) T cells induced smaller demyelinated lesions and showed reduced spread and accumulation within the CNS, corresponding with impaired extracellular-matrix-mediated migration. Hence, integrin β3 is required for Th17 cell-mediated autoimmune CNS inflammation.

16 July 2009 in Blood
Verified
Journal Article
Closed access
GMGerard Hernandez Mir
Gerard Hernandez Mir
JHJari Helin
Jari Helin
KSKari-Pekka Skarp
Kari-Pekka Skarp
RCRichard D. Cummings
Richard D. Cummings
AMAntti Mäkitie
Antti Mäkitie
ALAnne Leppänen
Anne Leppänen
Endothelial sialomucin CD34 functions as an L-selectin ligand mediating lymphocyte extravasation only when properly glycosylated to express a sulfated carbohydrate epitope, 6-sulfo sialyl Lewis x (6-sulfo SLex). It is thought that multivalent 6-sulfo SLex expression promotes high-affinity binding to L-selectin by enhancing avidity. However, the reported low amount of 6-sulfo SLex in total human CD34 is inconsistent with this model and prompted us to re-evaluate CD34 glycosylation. We separated CD34 into 2 glycoforms, the L-selectin–binding and nonbinding glycoforms, L-B-CD34 and L-NB-CD34, respectively, and analyzed released O- and N-glycans from both forms. L-B-CD34 is relatively minor compared with L-NB-CD34 and represented less than 10% of total tonsillar CD34. MECA-79, a mAb to sulfated core-1 O-glycans, bound exclusively to L-B-CD34 and this form contained all sulfated and fucosylated O-glycans. 6-Sulfo SLex epitopes occur on core-2 and extended core-1 O-glycans with approximately 20% of total L-B-CD34 O-glycans expressing 6-sulfo SLex. N-glycans containing potential 6-sulfo SLex epitopes were also present in L-B-CD34, but their removal did not abolish binding to L-selectin. Thus, a minor glycoform of CD34 carries relatively abundant 6-sulfo SLex epitopes on O-glycans that are important for its recognition by L-selectin.

1 April 2017 in Cytokine
Verified
Journal Article
Closed access
MSMichelle R. Simpson-Abelson
Michelle R. Simpson-Abelson
GHGerard Hernandez-Mir
Gerard Hernandez-Mir
ECErin E. Childs
Erin E. Childs
JCJ. Agustin Cruz
J. Agustin Cruz
APAmanda C. Poholek
Amanda C. Poholek
MMMandy J. McGeachy
Mandy J. McGeachy

1 August 2019 in The Journal of Immunology
Verified
Journal Article
Closed access
PDF file
GHGerard Hernandez-Mir
Gerard Hernandez-Mir
IRItay Raphael
Itay Raphael
SRShankar Revu
Shankar Revu
CPCatherine H. Poholek
Catherine H. Poholek
LALyndsay Avery
Lyndsay Avery
MMMandy J. McGeachy
Mandy J. McGeachy
β-site amyloid precursor protein-cleaving enzyme 1 (BACE1) is best known for its role in Alzheimer9s disease amyloid plaque formation but also contributes to neurodegenerative processes triggered by CNS injury. In this article, we report that BACE1 is expressed in murine CD4+ T cells and regulates signaling through the TCR. BACE1-deficient T cells have reduced IL-17A expression under Th17 conditions and reduced CD73 expression in Th17 and inducible T regulatory cells. However, induction of the Th17 and T regulatory transcription factors RORγt and Foxp3 was unaffected. BACE1-deficient T cells showed impaired pathogenic function in experimental autoimmune encephalomyelitis. These data identify BACE1 as a novel regulator of T cell signaling pathways that impact autoimmune inflammatory T cell function. Key Points BACE1 is expressed in CD4+ T cells and regulates signaling events during activation. BACE1-deficient T cells show reduced IL-17A expression in vitro. BACE1−/− Th17 cells have impaired pathogenicity in EAE.

13 March 2017 in PLOS ONE
Verified
Journal Article
Open access
PDF file
GHGerard Hernandez-Mir
Gerard Hernandez-Mir
MMMandy J. McGeachy
Mandy J. McGeachy
CD73 works together with CD39 to convert extracellular ATP to immunoregulatory adenosine, thus inhibiting inflammation. TGFβ-mediated CD73 expression on ‘regulatory’ Th17 cells limits their ability to eradicate tumors, similar to the immunosuppressive mechanism described for CD73 on Tregs. However, CD73 is also expressed on Th17 cells thought to be inflammatory in Crohn’s disease. CD73 has previously been reported to contribute to inflammation in the central nervous system (CNS). In experimental autoimmune encephalomyelitis (EAE), we found that inflammatory cytokine-producing Th17 cells showed increased CD73 expression as disease progressed. We therefore hypothesized that CD73 could be important for limiting the expansion or pathogenic function of Th17 cells in autoimmune inflammation of the CNS. Surprisingly, EAE development was not enhanced or inhibited by CD73 deficiency; there was correspondingly no difference in induction of Th17-associated cytokines IL-17, IFNγ or GM-CSF or recruitment of either inflammatory or regulatory cells to the central nervous system. We confirmed that CD73 was similarly not required for differentiation of Th17 cells in vitro. These data show that while CD73 expression is regulated during EAE, this enzyme is not absolutely required to either promote or limit Th17 cell expansion or EAE severity.